Other papers suggest including other biomarkers, such as CA-19-9 and carcinoembryonic antigen, to separate primary ovarian cancer from gastrointestinal cancer or pancreatic cancer in the investigation of patients with unknown ovarian masses,2,3,24 especially if they have a previous history of malignant disease, as we found that metastasis to the ovary can occur up to 11 years after the original cancer diagnosis. Here, CEACAM5 is linked to pancreatic neoplasm.